Not yet recruiting
Non-small cell lung cancer metastatic
Not yet recruitingStudy of MIDRIX-LUNG immunotherapy combined with anti-PD-1 treatment in patients with metastatic non-small-cell lung cancer
Registered drugNo placebo
Study of MIDRIX-LUNG immunotherapy combined with anti-PD-1 treatment in patients with metastatic non-small-cell lung cancer
Registered drugNo placebo
- Disease:Non-small cell lung cancer metastatic
- Substances:CarboplatinCemiplimab+5
Countries:
Belgium
Belgium- Participants:18–64 years · 65+ years
- Substances:Carboplatin